Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Authors:
- 9 December 2009
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 29 (2) , 316-322
Abstract
Summary Purpose To assess the safety, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT), of motexafin gadolinium (MGd), given in combination with doxorubicin, in patients with advanced solid tumors. Study Design The combination of MGd and doxorubicin was administered every 28 days (cycle 1) and then every 21 days (subsequent cycles). The dose of MGd, given daily for 3 days, was escalated from 1.0 mg/kg/d to 3.3 mg/kg/d, while the dose of doxorubicin was held at 30 mg/m2. Results Fifteen patients received 37 cycles of treatment, for a median of 2 cycles per patient (range 0–6 cycles). Three patients (20%) completed 6 cycles of therapy. The MTD was identified as MGd, 2 mg/kg/day and doxorubicin, 30 mg/m2. Dose limiting toxicities included grade 3 hypertension, pneumonia, bacteremia, and elevated GGT. Serious adverse events also included pulmonary embolism and urinary tract infection requiring hospitalization. There was no exacerbation of cardiac toxicity. No patients attained a response to treatment. Six patients (54%) had stable disease. The median time to disease progression, or to last assessment, was 49 days (range 8–195 days). Conclusions The combination of MGd and doxorubicin was fairly well tolerated. However, due to emerging preclinical data suggesting that MGd inhibits ribonucleotide reductase, further development of the combination of MGd plus doxorubicin is not recommended.Keywords
This publication has 16 references indexed in Scilit:
- Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non–Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Effects of motexafin gadolinium on DNA damage and X-ray-induced DNA damage repair, as assessed by the Comet assayInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Motexafin Gadolinium Disrupts Zinc Metabolism in Human Cancer Cell LinesCancer Research, 2005
- Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cellsBlood, 2005
- Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancerCurrent Opinion in Oncology, 2004
- The emerging role of reactive oxygen species in cancer therapyEuropean Journal of Cancer, 2004
- Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain MetastasesJournal of Clinical Oncology, 2003
- Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients With Brain MetastasesJournal of Clinical Oncology, 2001
- Adriamycin and its iron(III) and copper(II) complexesBiochemical Pharmacology, 1988
- ADRIAMYCIN-INDUCED DELAYED ERYTHROPOIETIC INJURY EXPRESSED FOLLOWING ANEMIA STRESS1980